Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids
Status:
Not yet recruiting
Trial end date:
2024-08-13
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of
naldemedine and nor-naldemedine after a single oral dose of naldemedine in pediatric
participants who are receiving or about to receive opioids.